4 tools to fight fraud, counterfeits and cyberattacks in the COVID-19 vaccine supply chain

The Moderna, Pfizer and most recently Johnson & Johnson vaccines have received emergency use authorization from the Food and Drug Administration, while AstraZeneca plans to soon submit its vaccine for review by the agency.

That means multiple vaccines with different supply chains and global distribution, trickling down to diverse administration sites.

“In isolation, we’re not dealing with things that are horrifically complex,” said Simon Geale, senior vice president of client solutions for Proxima, procurement specialists. “But if you put them all together, you end up with one of the most complex operations you’ve ever seen, and it’s different in every country.”